Monte Rosa Therapeutics (GLUE) Earnings Date & Reports

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

GLUE is expected to report earnings to rise 21.81% to -43 cents per share on May 08

Monte Rosa Therapeutics GLUE Stock Earnings Reports

Q1'25

Est.

$-0.44

Q4'24

Missed

by $0.54

Q3'24

Beat

by $0.18

Q2'24

Beat

by $0.09

Q1'24

Beat

by $0.06

The last earnings report on March 20 showed earnings per share of -35 cents, missing the estimate of 18 cents. With 614.96K shares outstanding, the current market capitalization sits at 271.26M.

View a ticker or compare two or three

Compare

GLUE